oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS
Department of Neurology, Östersund Hospital, Östersund, Sweden; Neurology Unit, Department of Pharmacology and Clinical Neuroscience, Umeå University, Östersund, Sweden.
Neurology Unit, Department of Pharmacology and Clinical Neuroscience, Umeå University, Östersund, Sweden.
Unit of Research, Education and Development, Östersund Hospital, Region Jämtland Härjedalen, Sweden, Östersund.
Örebro University, School of Medical Sciences. Department of Neurology.
Show others and affiliations
2016 (English)In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970Article in journal (Refereed) Epub ahead of print
Abstract [en]

Objective: New disease-modifying treatment strategies in multiple sclerosis offer possibilities for individualised treatment. In this study, we evaluated patient-reported outcome measures before and after a switch in therapy from first-line injectable treatments to rituximab.

Method: A total of 75 patients with clinically stable relapsing-remitting multiple sclerosis (RRMS) receiving ongoing first-line injectable treatment at three Swedish centres had their treatment switched to rituximab in this open-label phase II multicentre study. Assessment of treatment satisfaction, patient-perceived impact of the disease on daily life, fatigue, cognitive symptoms and disease progression was performed 3 months before and at the time of the treatment shift and then for a subsequent 2-year period.

Results: The overall treatment satisfaction rating improved significantly from a mean of 4.8 (scale range: 1-7), while on injectable therapies, to a mean of 6.3 after 1 year of rituximab treatment (p < 0.001). This improvement was sustained after 2 years. There was no significant change in scores for patient-perceived impact of disease, fatigue or disease progression.

Conclusion: A shift in therapy from first-line injectables to rituximab in a cohort of clinically stable RRMS patients was followed by improved treatment satisfaction. This is clinically relevant as it may influence long-term adherence to immunomodulating therapy.

Place, publisher, year, edition, pages
London, United Kingdom: Sage Publications, 2016.
Keyword [en]
Multiple sclerosis, rituximab, B-cell depletion therapy, treatment satisfaction, patientreported outcome measures, clinical trial
National Category
Neurology
Identifiers
URN: urn:nbn:se:oru:diva-53360DOI: 10.1177/1352458516676643PubMedID: 27780912OAI: oai:DiVA.org:oru-53360DiVA: diva2:1044202
Available from: 2016-11-02 Created: 2016-11-02 Last updated: 2016-11-02Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Gunnarsson, Martin
By organisation
School of Medical Sciences
In the same journal
Multiple Sclerosis
Neurology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 15 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf